AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Molecular Signatures in Inflammatory Skin Disease

Recruitingn/aAges any - anyAllProf. Dr. Stephan Weidinger
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol * Dermatologist-diagnosed chronic inflammatory skin disease * Subject receives systemic therapy within routine care (in-label use of biologics) Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. * Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
๐Ÿ’Š

What it tests

  • Anti-TNF
  • Anti-IL12/23
  • Anti-IL17
  • Dupilumab
  • Anti-IL23
๐Ÿ“

Where

1 site
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel
Kiel, Germany
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy